Anti-HIV drug splits opinion

• Autores: Clare Wilson
• Localización: New scientist, ISSN 0262-4079, Nº. 3050, 2015, pág. 14
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Wilson talks about the Truvada, a drug that one can take before and after sex to help reduce the risk of human immunodeficiency virus (HIV) infection. It contains two antiviral drugs, tenofovir and emtricitabine, also given to people infected with HIV, which stop the virus multiplying. On the face of it, having any kind of unprotected sex seems risky. Yet Truvada users are making highly nuanced decisions about their risks. In the West, such pre-exposure prophylaxis (PrEP), has mainly been studied in gay men. Most trial participants used condoms some of the time, only forgoing them when it seemed safe, after asking their partners when they were last tested and when they'd had unsafe sex. One trial of daily Truvada showed that the drug did reduce condom use, yet sexually transmitted disease rates stayed the same, perhaps because people were good at assesssing their partner's sexual history. It's less clear how well PrEP works in people having heterosexual sex